Previous Article | Next Article ![]()
Applied and Environmental Microbiology, May 2009, p. 2638-2642, Vol. 75, No. 9
0099-2240/09/$08.00+0 doi:10.1128/AEM.02214-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Department of Pathology, Bacteriology and Avian Diseases, Research Group for Veterinary Public Health and Zoonoses, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium,1 Research Program in Cellular Biotechnology, Institute of Biotechnology, Viikki Biocenter, P.O. Box 56, Viikinkaari 9, FIN-00014 University of Helsinki, Finland,2 Division of Genetics and Physiology, Department of Biology, Vesilinnantie 5, FIN-20014 University of Turku, Finland3
Received 25 September 2008/ Accepted 22 February 2009
|
|
|---|
|
|
|---|
Understanding the pathogenesis of these infections is of crucial importance for the development of new tools for the prevention and control of C. perfringens-related diseases. Genetic modification is a valuable approach to identify new virulence factors and to study their role in the pathogenesis of C. perfringens.
Since the 1980s, several tools for manipulation of C. perfringens at the molecular level have been developed (1, 5, 28, 35, 38). Among these tools, transposon mutagenesis is a method that is widely used for identification of virulence genes. Until now, the only reproducible method for transposon mutagenesis in C. perfringens was based on Tn916, a tetracycline resistance-encoding conjugative transposon originally isolated from Enterococcus faecalis (10, 11, 13). Tn916 has been used extensively for transposon mutagenesis due to its broad host range and has been proven to be valuable for the identification of genes in C. perfringens (3, 7, 22). Nevertheless, this method has major disadvantages; multiple Tn916 insertion events occur with an incidence of 65% to 75%, severely complicating identification of genes responsible for phenotype changes (3, 7, 19). Furthermore, Tn916 is still active after insertion, resulting in unstable mutants (6, 39, 42). To our knowledge, generation of Tn916-derived transposon mutants in C. perfringens field strains has never been described.
Although a variety of transposon mutagenesis methods are available for gram-positive bacteria (4, 37, 41, 43), the inherent species nonspecificity, as well as the lack of mobility of the integrated transposon, makes the bacteriophage Mu-based transposon delivery system a system of choice for a variety of species (16, 26, 46). The Mu transposition approach includes in vitro assembly of a complex between the transposon DNA and the transposase enzyme, the transpososome, followed by delivery of the transpososome into the recipient cells. Once inside a cell, the Mu transpososome becomes activated in the presence of divalent cations, resulting in genomic integration of the delivered transposon. The bacteriophage Mu transposition system is also functional in vitro (15, 32, 33), in contrast to the Tn916 mutagenesis strategy, which is restricted to transposon mobilization in vivo following conjugation or electroporation. Under the optimal in vitro conditions, the Mu transposition reaction requires only the MuA transposase, a mini-Mu transposon, and target DNA as macromolecular components (15).
In this study, a novel protocol is described for transposon mutagenesis in C. perfringens that exploits the bacteriophage Mu transposition system. To our knowledge, this report is the first report describing a mutagenesis method generating single-insertion transposon mutants in laboratory and field isolates of C. perfringens. This method is important for the identification of C. perfringens virulence factors involved in the numerous diseases caused by this bacterium.
|
|
|---|
(45) was used for routine plasmid DNA isolation. C. perfringens strains were grown anaerobically at 37°C in brain heart infusion broth (Oxoid, Basingstoke, United Kingdom) or TGY broth (30 g tryptone [Oxoid], 20 g Bacto yeast extract [BD Biosciences, San Jose, CA], 1 g glucose [Sigma, St. Louis, MO], and 1 g L-cysteine [Sigma]). The solid medium used for C. perfringens consisted of 3.9% Colombia agar base (Oxoid) supplemented with 5% defibrinated sheep blood (International Medical, Brussels, Belgium) or 2% egg yolk in plates (referred to below as egg yolk agar plates).
E. coli DH5
was grown aerobically at 37°C in Luria broth (Sigma).
When appropriate, plasmid maintenance and genomic transposon insertions were selected by addition of erythromycin (Sigma) to the growth media at the following concentrations: for E. coli, 200 µg/ml; and for C. perfringens, 10 µg/ml.
Plasmids.
Plasmid pLEB620 is a pUC19-derived carrier plasmid for the Em-Mu minitransposon (26). Em-Mu includes the ermB gene from Lactobacillus reuteri, which encodes resistance to macrolides, lincosamides, and streptogramin B antibiotics. In the transposon termini as an inverted repeat, the resistance cassette is flanked by a pair of 50-bp segments from the Mu right end, including critical MuA transposase binding sites (26, 33). Plasmid pTCATT is a derivative of the E. coli-C. perfringens shuttle vector pJIR410 (8). Besides the ermB gene, pTCATT carries the open reading frame of catP and can therefore be used as a reporter system. In this work, pTCATT was used as a replicative control plasmid to determine the competency statuses of the strains.
Electrocompetent cells.
Electrocompetent E. coli cells were prepared essentially as described by Sambrook and Russell (30). Electrocompetent C. perfringens cells were prepared using the method of Scott and Rood (35), with minor modifications.
C. perfringens cells were cultured overnight in liquid brain heart infusion medium and diluted 1:30 in 12 ml of TGY broth. The cells were grown to an optical density of 0.2 to 0.3 and harvested by centrifugation at 4,300 rpm (
650 x g) for 20 min at 21°C. The cells were then rinsed twice with 1.2 ml of electroporation buffer (272 mM sucrose, 7 mM sodium phosphate buffer [pH 7.4]). Between the rinse steps, the cells were collected by centrifugation at 13,000 rpm (
1,250 x g) for 10 min at 21°C. After the second rinse, 1.2 ml of electroporation buffer containing lysostaphin (Sigma) was added, and the cells were incubated for 1 h at 37°C. The two rinse steps with electroporation buffer were repeated. Finally, the cells were resuspended in 1.2 ml of electroporation buffer and divided into 400-µl aliquots.
Isolation of the Em-Mu transposon and transpososome assembly.
For transposon mutagenesis in C. perfringens, the Em-Mu minitransposon was used (26). Isolation of the Em-Mu transposon and transpososome assembly were performed as described by Pajunen et al. (26). Briefly, plasmid pLEB620 containing the Em-Mu transposon was propagated in E. coli DH5
and isolated using a plasmid midi kit (Qiagen, Hilden, Germany).
The Em-Mu transposon was released from pLEB620 by BglII (Sigma) digestion. The digested DNA was extracted sequentially using phenol and chloroform and concentrated by ethanol precipitation. The transposon fragment was purified chromatographically using an anion-exchange column (MonoQ HR 5/5; Pharmacia Amersham Biosciences, Piscataway, NJ). Fractions containing Em-Mu were pooled and concentrated by ethanol precipitation.
The in vitro transpososome assembly reaction mixture (80 µl) consisted of 4.4 pmol Em-Mu, 19.6 pmol (1,600 ng) MuA transposase (Finnzymes, Espoo, Finland), 50% (vol/vol) glycerol, 150 mM Tris (pH 6), 0.025% Triton X-100, 150 mM NaCl, and 0.1 mM EDTA. The reaction was carried out at 30°C for 4 h. Eight transpososome assembly reaction mixtures were pooled and concentrated by polyethylene glycol precipitation essentially as described previously (31). The pellet was resuspended in 50 µl TGD buffer (10 mM Tris-HCl [pH 6], 0.5% glycerol, 0.1 M dithiothreitol). Transposition complexes were stored at –80°C unless otherwise indicated. Successful complex assembly was monitored on 2% agarose (Nusieve 3:1; Cambrex) gels containing 87 µg/ml of heparin and 87 µg/ml of bovine serum albumin as described previously (21).
Transposon mutagenesis.
For electroporation, electrocompetent cells (400 µl) were mixed with the transpososome preparation (1 µl) on ice and transferred to a prechilled 0.2-cm electrode spacing cuvette (Bio-Rad, Hercules, CA). The cells were incubated on ice for 10 min. Electroporation was then performed with a Gene Pulser Xcell electroporation system (Bio-Rad) using the following settings: 400
, 1.25 kV, and 25 µF. Following the pulse, the cells were incubated on ice for 10 min and then transferred to 1 ml of TGY broth containing 10 mM MgCl2. JIR325 cells were incubated for 2 h at 37°C following the pulse. Depending on the protocol being tested, cells of field isolate 56 were incubated for 3 h at 37°C or for 4 h at 20°C or 30°C following the pulse. In the optimized protocol for field isolate 56, the cells were first incubated at 37°C, and then 1 µg/ml of erythromycin was added and the cells were incubated for another 1 h at 37°C in the presence of erythromycin. Following a total incubation time of 2, 3, or 4 h, the transformed cells were plated on egg yolk agar plates containing 10 µg/ml of erythromycin.
Southern blotting.
Genomic DNA was isolated from C. perfringens using the cetyltrimethylammonium bromide method (44) and was subsequently digested with PsiI (Fermentas, Burlington, Canada). The resulting fragments were separated by agarose gel electrophoresis and subsequently transferred onto a nylon membrane (Roche Diagnostics, Basel, Switzerland) with 1x SSC (0.15 M NaCl plus 0.015 M sodium citrate; Roche Diagnostics). Fixation was done by heating the membrane for 2 h at 80°C. A digoxigenin (DIG)-labeled Em-Mu probe was synthesized with a PCR DIG probe synthesis kit (Roche Diagnostics) using the following primers: Em-Mu probe fw (ACTGAATACTCGTGTCAC) and Em-Mu probe rev (GTCAGATAGATGTCAGACGC). For hybridization and immunodetection, a DIG Easy Hyb wash and block buffer set and CDP-Star (Roche Diagnostics) were used according to the manufacturer's guidelines.
Identification of transposon-flanking genome sequences.
To amplify the transposon-flanking genome sequences, a modification of the method of Kwon and Ricke (20) was used. Genomic DNA was prepared and digested with XapI (Fermentas). The Y-linkers were prepared as described previously (20) by annealing the following two oligonucleotides: Linker 1 (TTTCTGCTCGAATTCAAGCTTCTAACGATGTACGGGGACA) and Linker 2 (AATTTGTCCCCGTACATCGTTAGAACTACTCGTACCATCCACAT). The DNA fragments were ligated to Y-linkers (20) using T4 DNA ligase (Invitrogen, Merelbeke, Belgium). For amplification of the genome regions 5' and 3' of the inserted transposon, the primer pair Y-linker primer (CTGCTCGAATTCAAGCTTCT) and Em-Mu seq rev (ATCAGCGGCCGCGATC) and the primer pair Y-linker primer and Em-Mu seq fw (TCTGCAGACGCGTCGACGTCA), respectively, were used. Nucleotide sequences were analyzed using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA), a DyeEx 2.0 spin kit (Qiagen), and an ABI Prism 3100 genetic analyzer (Applied Biosystems).
Genomic transposon insertion sites were identified by comparing the sequences to the publicly available genomic sequences of C. perfringens strains 13, ATCC 13124, and SM101, using BLAST on the European Bioinformatics Institute server.
|
|
|---|
As the electroporation efficiency is the key factor affecting bacteriophage Mu transpososome delivery, an optimal electroporation protocol needed to be generated for C. perfringens. To prevent premature activation of the transpososome, contact with divalent cations outside the bacterium should be avoided, and therefore, electroporation buffers should be prepared without Mg2+ or Ca2+ ions. Several electroporation protocols (1, 7, 18, 35) were tested for field isolate 56. The highest electroporation yield, obtained using control plasmid pTCATT containing an erythromycin resistance gene, was generated with the modified protocol of Scott and Rood (35). Due to the altered ion content of the Mg2+- and Ca2+-free buffer (272 mM sucrose, 7 mM sodium phosphate buffer [pH 7.4]), new electroporation parameters needed to be established. The optimal settings were determined to be 400
, 1.25 kV, and 25 µF. Electrocompetent cells of both laboratory strain JIR325 and field isolate 56 were prepared using the same protocol, except for the concentration of lysostaphin used. As field isolate 56 appeared to be more sensitive to lysostaphin, a lower concentration of this compound (2 µg/ml) was used for this isolate than for strain JIR325 (10 µg/ml). Electrocompetent cells of field isolate 56 could not be stored at –80°C but needed to be freshly prepared prior to electroporation.
Transposon mutagenesis.
In each electroporation experiment, 1 µl of a transpososome preparation was delivered into strain JIR325 or isolate 56 cells. Following the pulse, the transformants were allowed to recover in TGY broth before antibiotic selection was applied on egg yolk agar plates containing 10 µg/ml erythromycin. For strain JIR325, incubation for 2 h in nonselective TGY broth was sufficient to allow plating on selective agar plates. However, transformants of field isolate 56 required an incubation time of 3 h in nonselective medium. Sequencing data (not shown) revealed that 3 h of incubation in nonselective medium resulted in the presence of multiple identical mutants in each batch. Thus, several strategies to prevent mutant amplification in nonselective TGY broth were tested. A decrease in the incubation temperature to 20°C or 30°C combined with a longer incubation time appeared to be unsuccessful. Finally, erythromycin was added to the incubation medium at a concentration below the MIC for both strains (i.e., 1 µg/ml) after 1 h of incubation; the transformants could be plated on selective agar plates 2 h after the pulse, and multiplication of the mutants was avoided.
The yield of transposon mutants fluctuated depending on the quality of the electrocompetent cells used. As a control, plasmid pTCATT was electroporated with each batch of electrocompetent cells. An absence or a low yield of transposon mutants was consistently reflected in the absence or low number of positive transformants obtained with pTCATT. Following electroporation of plasmid pTCATT, the numbers of erythromycin-resistant bacteria obtained for strain JIR325 and isolate 56 were 32,700 and 23,600 CFU/µg plasmid DNA, respectively. Reflecting this difference in the competency statuses of these strains, the yield of transposon mutants was higher for laboratory strain JIR325 (239 CFU/µg transposon) than for field isolate 56 (134 CFU/µg transposon). A total of 3,200 mutants of field isolate 56 were obtained.
The level of efficiency of the Em-Mu transposon insertion into C. perfringens is workable and is intermediate compared to the levels for other gram-positive bacteria. The yield is similar to the yields obtained with Streptococcus suis (100 CFU/µg DNA) and Lactococcus lactis (110 CFU/µg DNA), lower than the yields obtained with Staphylococcus aureus (20,000 or 12,000 CFU/µg transposon DNA depending on the strain), and higher than the yield obtained with Streptococcus pyogenes (10 CFU/µg transposon) (26, 46). Compared to the efficiency in gram-negative bacteria, the efficiency in C. perfringens is 2 to 3 orders of magnitude lower (21).
Genomic integration.
A PCR was performed to confirm the presence of the Em-Mu transposon in the genomic DNA of 50 mutants. Genomic DNA from 30 erythromycin-resistant isolate 56 mutants was obtained, digested with PsiI, which does not cut transposon DNA, and analyzed by Southern hybridization with a DIG-labeled Em-Mu transposon probe. All of the mutants analyzed contained a single copy of the Em-Mu transposon. The results of Southern blotting for seven mutants are shown in Fig. 1.
![]() View larger version (76K): [in a new window] |
FIG. 1. Southern blot detection of genomic fragments harboring the Em-Mu transposon insertion. Genomic DNAs from mutants M1 to M7 (lanes 1 to 7) and wild-type parental strain 56 (lane 8) were digested with PsiI and hybridized with a DIG-labeled probe for the Em-Mu transposon. Lane 9 contained purified Em-Mu transposon (1.4 kb) as a positive control. Lane M contained a DIG-labeled DNA molecular weight marker (Roche Diagnostics); the fragment sizes are (from top to bottom) 23.1, 9.4, 6.5, and 4.3 kb.
|
|
View this table: [in a new window] |
TABLE 1. Integration sites of transposons in the mutants derived from field isolate 56a
|
In conclusion, a new protocol for transposon mutagenesis in C. perfringens that is based on the bacteriophage Mu DNA transposition system was developed. The method described is better than the protocols based on Tn916 used previously since mutants containing only a single copy of the transposon are generated and the proportion of hits in protein-encoding genes is higher. Furthermore, the method is also applicable to field isolates of C. perfringens, if they can be made electrocompetent.
This work was supported by the Institute for Science and Technology, Flanders (IWT). F.V.I. was supported by a postdoctoral research grant from the Research Foundation—Flanders (FWO) and by the Research Fund of Ghent University.
Published ahead of print on 6 March 2009. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»